Comparative Pharmacology
Head-to-head clinical analysis: CODEINE ASPIRIN APAP FORMULA NO 3 versus METHADOSE.
Head-to-head clinical analysis: CODEINE ASPIRIN APAP FORMULA NO 3 versus METHADOSE.
CODEINE, ASPIRIN, APAP FORMULA NO. 3 vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug that is metabolized to morphine, a mu-opioid receptor agonist, which activates descending pain pathways and alters pain perception. Aspirin irreversibly inhibits cyclooxygenase-1 and -2, reducing prostaglandin synthesis and inflammation. Acetaminophen (APAP) acts centrally to inhibit cyclooxygenase and activate descending serotonergic pathways, though its exact mechanism is unclear.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
1-2 tablets orally every 4-6 hours as needed for pain. Each tablet contains codeine 30 mg, aspirin 325 mg, acetaminophen 325 mg. Maximum: 12 tablets per day.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Codeine: 2.5-3.5 hours. Aspirin: 15-20 minutes for parent drug, but salicylate half-life is dose-dependent (2-3 hours at low doses, up to 15-30 hours at anti-inflammatory doses). Acetaminophen: 1.5-3 hours (prolonged in liver disease or overdose).
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Codeine: Renal (up to 90% as metabolites, ~10% unchanged). Aspirin: Renal (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as gentisic acid). Acetaminophen: Renal (85-90% as glucuronide/sulfate conjugates, 5-10% unchanged).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist